TerminatedPhase 2NCT00412841

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus

Studying Avascular necrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NYU Langone Health
Principal Investigator
Howard M Belmont, M.D.
The New York University Hospital for Joint Diseases
Intervention
Atorvastatin(drug)
Enrollment
43 enrolled
Eligibility
18-75 years · FEMALE
Timeline
20022008

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00412841 on ClinicalTrials.gov

Other trials for Avascular necrosis

Additional recruiting or active studies for the same condition.

See all trials for Avascular necrosis

← Back to all trials